Related Experiment Video
Updated: Oct 19, 2025
08:44
Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
Published on: May 30, 2020
6.2K
Racial/ethnic differences in eligibility for asthma biologics among pediatric populations
Eric M Wohlford1, Peter F Huang2, Jennifer R Elhawary2
1Division of Pediatric Allergy and Immunology, University of California San Francisco, San Francisco, Calif; Department of Medicine, University of California San Francisco, San Francisco, Calif.
The Journal of Allergy and Clinical Immunology
|September 18, 2021
Summary
Asthma outcomes and biologic therapy eligibility vary by race/ethnicity in children. Blood markers and asthma subtypes show population-specific links to exacerbations, impacting treatment access for minority groups.
Area of Science:
- Pediatric Allergy and Immunology
- Genetics and Genomics in Medicine
- Health Disparities Research
Background:
- Asthma heterogeneity necessitates understanding population-specific clinical differences.
- Race/ethnicity influences clinical blood parameters, asthma subtypes, and outcomes.
- Data on these differences in minority pediatric populations are limited.
Purpose of the Study:
- Investigate associations between blood parameters, asthma subtypes, and asthma outcomes in minority children.
- Examine population-specific eligibility for biologic therapies.
- Address disparities in asthma care for pediatric minority populations.
Main Methods:
- Utilized data from two pediatric asthma case-control studies.
- Performed logistic regressions to link blood parameters and asthma subtypes to outcomes.
- Analyzed race/ethnicity interactions and therapeutic eligibility using chi-square tests.
Main Results:
- Race/ethnicity modified the association between total IgE and asthma exacerbations.
- Specific asthma subtypes (allergic, eosinophilic) showed worse outcomes in different ethnic groups.
- Biologic therapy eligibility varied significantly across racial/ethnic pediatric populations.
Conclusions:
- Population-specific associations exist between blood markers, asthma subtypes, and outcomes.
- Pediatric racial/ethnic groups show differential eligibility for asthma biologic therapies.
- Further research in diverse populations is crucial for equitable asthma treatment.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
3.3K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
01:30Asthma-IV: Diagnostic and Management
2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
687
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
687
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
31
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
31
01:19Antiasthma Drugs: Leukotriene Modifiers
688
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
688
01:20Asthma: Pathogenesis and Management
836
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
836